English
|
Español
English
|
Español
Insurance
Marketing
Pharmaceuticals
Technology/Innovation
Regulatory
Community
Astrazeneca
Press release submission
| Sep 16, 2018
ASTRAZENECA: US FDA approves LUMOXITI™ (moxetumomab pasudotox-tdfk) for certain patients with relapsed or refractory hairy cell leukemia
Marian Johns
| Jan 17, 2018
FDA approves Lynparza as first PARP Inhibitor for treating metastatic breast cancer
Trending
+
Pharmaceuticals
Patient Daily
| Oct 22, 2024
Bristol Myers Squibb funds $2.25M cervical cancer project in Malawi
+
Pharmaceuticals
Patient Daily
| Oct 21, 2024
Baylor professors Bottazzi and Davis elected to National Academy of Medicine
+
Pharmaceuticals
Patient Daily
| Oct 22, 2024
American Lung Association welcomes three leaders to Georgia board
+
Pharmaceuticals
Patient Daily
| Oct 24, 2024
Dr. Huda Zoghbi honored by American Academy for her contributions to science
